Bank of New York Mellon’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-350,044
| Closed | -$46.2M | – | 4319 |
|
|
2025
Q1 | $46.2M | Sell |
350,044
-9,001
| -3% | -$1.12M | 0.01% | 1019 |
|
|
2024
Q4 | $30M | Buy |
359,045
+8,330
| +2% | +$685K | 0.01% | 1327 |
|
|
2024
Q3 | $25.7M | Buy |
350,715
+1,567
| +0.4% | +$118K | ﹤0.01% | 1437 |
|
|
2024
Q2 | $23.9M | Sell |
349,148
-27,123
| -7% | -$1.88M | ﹤0.01% | 1464 |
|
|
2024
Q1 | $26M | Sell |
376,271
-39,013
| -9% | -$2.68M | 0.01% | 1424 |
|
|
2023
Q4 | $29.7M | Buy |
415,284
+10,955
| +3% | +$630K | 0.01% | 1385 |
|
|
2023
Q3 | $21.1M | Buy |
404,329
+6,182
| +2% | +$360K | ﹤0.01% | 1512 |
|
|
2023
Q2 | $25.2M | Buy |
398,147
+10,763
| +3% | +$671K | 0.01% | 1423 |
|
|
2023
Q1 | $21M | Sell |
387,384
-1,382
| -0.4% | -$66.8K | ﹤0.01% | 1522 |
|
|
2022
Q4 | $20.6M | Buy |
388,766
+207
| +0.1% | +$10.4K | ﹤0.01% | 1525 |
|
|
2022
Q3 | $18.1M | Buy |
388,559
+5,171
| +1% | +$270K | ﹤0.01% | 1558 |
|
|
2022
Q2 | $21.9M | Sell |
383,388
-2,120
| -0.5% | -$120K | 0.01% | 1485 |
|
|
2022
Q1 | $23.6M | Buy |
385,508
+18,999
| +5% | +$987K | ﹤0.01% | 1556 |
|
|
2021
Q4 | $19.2M | Buy |
366,509
+21,218
| +6% | +$891K | ﹤0.01% | 1741 |
|
|
2021
Q3 | $12.9M | Buy |
345,291
+13,547
| +4% | +$471K | ﹤0.01% | 1983 |
|
|
2021
Q2 | $13.5M | Buy |
331,744
+26,788
| +9% | +$990K | ﹤0.01% | 1964 |
|
|
2021
Q1 | $10.3M | Buy |
304,956
+12,644
| +4% | +$439K | ﹤0.01% | 2069 |
|
|
2020
Q4 | $9.29M | Sell |
292,312
-19,194
| -6% | -$504K | ﹤0.01% | 2044 |
|
|
2020
Q3 | $7.99M | Buy |
311,506
+61,336
| +25% | +$1.4M | ﹤0.01% | 1968 |
|
|
2020
Q2 | $6.42M | Buy |
250,170
+18,143
| +8% | +$367K | ﹤0.01% | 2082 |
|
|
2020
Q1 | $3.57M | Buy |
232,027
+43,146
| +23% | +$937K | ﹤0.01% | 2252 |
|
|
2019
Q4 | $6.48M | Sell |
188,881
-1,316
| -0.7% | -$15.8K | ﹤0.01% | 2206 |
|
|
2019
Q3 | $1.42M | Sell |
190,197
-15,226
| -7% | -$146K | ﹤0.01% | 2941 |
|
|
2019
Q2 | $2.67M | Sell |
205,423
-9,568
| -4% | -$123K | ﹤0.01% | 2650 |
|
|
2019
Q1 | $2.62M | Buy |
214,991
+4,931
| +2% | +$63K | ﹤0.01% | 2646 |
|
|
2018
Q4 | $2.39M | Buy |
210,060
+2,516
| +1% | +$40.6K | ﹤0.01% | 2638 |
|
|
2018
Q3 | $4.5M | Buy |
207,544
+845
| +0.4% | +$17.7K | ﹤0.01% | 2456 |
|
|
2018
Q2 | $3.65M | Sell |
206,699
-2,057
| -1% | -$41.8K | ﹤0.01% | 2544 |
|
|
2018
Q1 | $4.39M | Sell |
208,756
-6,270
| -3% | -$122K | ﹤0.01% | 2417 |
|
|
2017
Q4 | $3.11M | Buy |
215,026
+45,897
| +27% | +$709K | ﹤0.01% | 2591 |
|
|
2017
Q3 | $2.67M | Sell |
169,129
-2,121
| -1% | -$31.1K | ﹤0.01% | 2670 |
|
|
2017
Q2 | $2.13M | Buy |
171,250
+24,055
| +16% | +$279K | ﹤0.01% | 2813 |
|
|
2017
Q1 | $2.39M | Sell |
147,195
-525
| -0.4% | -$7.6K | ﹤0.01% | 2742 |
|
|
2016
Q4 | $2.23M | Sell |
147,720
-10,479
| -7% | -$148K | ﹤0.01% | 2783 |
|
|
2016
Q3 | $2.41M | Sell |
158,199
-19,118
| -11% | -$773K | ﹤0.01% | 2641 |
|
|
2016
Q2 | $6.88M | Buy |
177,317
+28,467
| +19% | +$1.02M | ﹤0.01% | 2046 |
|
|
2016
Q1 | $4.14M | Sell |
148,850
-19,271
| -11% | -$642K | ﹤0.01% | 2274 |
|
|
2015
Q4 | $9.04M | Buy |
168,121
+32,470
| +24% | +$1.64M | ﹤0.01% | 1899 |
|
|
2015
Q3 | $5.43M | Sell |
135,651
-15,778
| -10% | -$515K | ﹤0.01% | 2186 |
|
|
2015
Q2 | $4.84M | Buy |
151,429
+50,649
| +50% | +$1.28M | ﹤0.01% | 2374 |
|
|
2015
Q1 | $2.41M | Buy |
100,780
+15,622
| +18% | +$350K | ﹤0.01% | 2736 |
|
|
2014
Q4 | $1.5M | Sell |
85,158
-1,579
| -2% | -$24.7K | ﹤0.01% | 3042 |
|
|
2014
Q3 | $1.19M | Buy |
86,737
+13,237
| +18% | +$199K | ﹤0.01% | 3188 |
|
|
2014
Q2 | $1.24M | Buy |
+73,500
| New | +$1.21M | ﹤0.01% | 3189 |
|
Other funds holding ITCI
KIM
HNB
Bank of New York Mellon's ITCI Position: Q2 2025 in Review
Bank of New York Mellon sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 350,044 shares — an estimated $46.2M sold.
Bank of New York Mellon first reported a position in ITCI in Q2 2014 and held it in 44 quarters. The position peaked at $46.2M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Bank of New York Mellon reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Bank of New York Mellon sold 350,044 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $46.2M.
- Bank of New York Mellon first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 44 quarters.
- Bank of New York Mellon's Intra-Cellular Therapies Inc. position peaked at $46.2M in Q1 2025.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.